Theory of relativity.
Another RELATIVITY trial demonstrates the promise of adding the LAG-3 inhibitor relatlimab to nivolumab for metastatic melanoma, not only upfront, but also after failing prior PD-L1 inhibition. | Asierto, J Clin Oncol 2023
Search This Blog
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
- Get link
- Other Apps
Comments
Post a Comment